Myeloproliferative Neoplasms | Specialty

Dr Kuykendall on the Relevance of QOL End Points in Myelofibrosis Clinical Trials

September 29th 2025

Andrew Kuykendall, MD, discussed the advantages and limitations of using QOL- and symptom-related end points in myelofibrosis clinical research.

Poll: Vote on the Top Breast Cancer, Hematology Abstracts to Watch at ESMO 2025

September 29th 2025

Dr Mascarenhas on the IMpact-MF Trial of Imetelstat in R/R Myelofibrosis

September 26th 2025

John Mascarenhas, MD, outlines the ongoing phase 3 IMpact-MF trial, evaluating imetelstat in relapsed/refractory myelofibrosis.

Real-World Data Show Hematologic Responses With Pacritinib in Myelofibrosis With Anemia

September 22nd 2025

Treatment with pacritinib in a real-world clinical setting led to hemoglobin responses in 44% of patients with myelofibrosis and anemia.

Dr Gangat on Ruxolitinib as the Standard of Care in Myelofibrosis

September 18th 2025

Naseema Gangat, MBBS, discusses the JAK inhibitor ruxolitinib as the standard of care for the treatment of patients with myelofibrosis.

Dr Kuykendall on Quality of Life Outcomes With Rusfertide in Polycythemia Vera

September 10th 2025

Andrew Kuykendall, MD, details the benefit of rusfertide regarding quality of life in patients with polycythemia vera compared with placebo.

SOHO Spotlight: Hematologists Share Practice-Informing Insights From the 2025 Annual Meeting

September 10th 2025

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

Dr Loghavi on SOC Frontline Testing Approaches in MDS

September 5th 2025

Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.

Venetoclax Plus Azacitidine Fails to Provide OS Advantage in Treatment-Naive, Higher-Risk MDS

September 4th 2025

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.

Revisit Every OncLive On Air Episode From August 2025

September 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

FDA Grants Breakthrough Therapy Designation to Rusfertide for Erythrocytosis in Polycythemia Vera

August 25th 2025

Rusfertide earned an FDA breakthrough designation for polycythemia vera based on findings from the phase 3 VERIFY study.

Divesiran Shows Promise as RNA-Based Approach in Polycythemia Vera

August 25th 2025

Marina Kremyanskaya, MD, PhD, discusses the investigation of divesiran in polycythemia vera.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Dr Kremyanskaya on the Ongoing Development of Divesiran for Polycythemia Vera

August 22nd 2025

Marina Kremyanskaya, MD, PhD, discusses early-phase findings with divesiran in patients with polycythemia vera.

Considerations for Selection and Sequencing in Polycythemia Vera and Myelofibrosis

August 21st 2025

Naseema Gangat, MBBS, delves into the role of ruxolitinib as a standard of care for the treatment of patients with polycythemia vera and myelofibrosis.

Dr Gangat on Reducing JAK2 Allele Burden With Ruxolitinib or Ropeginterferon Alfa-2b in Polycythemia Vera

August 19th 2025

Naseema Gangat, MBBS, discusses the potential use of ruxolitinib and ropeginterferon alfa-2b-njft to reduce JAK2 allele burden in polycythemia vera.

The OncFive: Top Oncology Articles for the Week of 8/10

August 16th 2025

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Dr Schetelig on Challenges Assessing Haploidentical vs Mismatched Transplantation in AML/ALL/MDS

August 15th 2025

Johannes Schetelig, MD, discusses challenges with assessing haploidentical related vs mismatched unrelated donor transplantation in high-risk AML/ALL/MDS

Clinical Development Is Discontinued for SGR-2921 in R/R AML and Higher-Risk MDS

August 15th 2025

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.

Consensus on Clinical Trial End Points Is Essential for Improved Drug Development Across MPNs

August 11th 2025

Andrew Kuykendall, MD, outlines the limitations of current clinical end points and discusses the need for molecularly informed drug development in MPN.